Calidi Biotherapeutics Announces Proposed Public Offering
Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has announced plans for a public offering of common stock and pre-funded warrants. The offering will be conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent.
The company intends to use the proceeds for working capital and general corporate purposes. The securities will be offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.
A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, providing detailed information about the offering terms.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI), un'azienda biotecnologica in fase clinica focalizzata su immunoterapie mirate, ha annunciato piani per un offerta pubblica di azioni ordinarie e warrant prefinanziati. L'offerta sarà condotta da Ladenburg Thalmann & Co. Inc. come agente di collocamento esclusivo.
L'azienda intende utilizzare i proventi per capitale circolante e scopi aziendali generali. I titoli saranno offerti tramite una dichiarazione di registrazione shelf su modulo S-3 che è stata dichiarata efficace dalla SEC il 10 ottobre 2024. La dimensione finale, i termini e il completamento dell'offerta sono soggetti a condizioni di mercato.
Un supplemento del prospetto preliminare e il prospetto accompagnatorio saranno depositati presso la SEC, fornendo informazioni dettagliate sui termini dell'offerta.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI), una empresa biotecnológica en etapa clínica centrada en inmunoterapias específicas, ha anunciado planes para una oferta pública de acciones comunes y garantías prefinanciadas. La oferta será realizada a través de Ladenburg Thalmann & Co. Inc. como agente de colocación exclusivo.
La empresa tiene la intención de utilizar los ingresos para capital de trabajo y fines corporativos generales. Los valores se ofrecerán a través de una declaración de registro de estantería en el formulario S-3 que fue declarada efectiva por la SEC el 10 de octubre de 2024. El tamaño final, los términos y la finalización de la oferta están sujetos a las condiciones del mercado.
Un suplemento de prospecto preliminar y el prospecto acompañante se presentarán ante la SEC, proporcionando información detallada sobre los términos de la oferta.
칼리디 바이오기술 (NYSE AMERICAN: CLDI), 표적 면역 요법에 집중하는 임상 단계의 생명공학 회사가 공모를 위한 계획을 발표했습니다. 이번 공모는 독점 배치 에이전트로서 Ladenburg Thalmann & Co. Inc.를 통해 진행됩니다.
회사는 운전 자본 및 일반 기업 용도에 사용할 수익을 의도하고 있습니다. 증권은 SEC에 의해 2024년 10월 10일에 효력 발생이 선언된 S-3 양식의 선반 등록 명세서를 통해 제공됩니다. 최종 규모, 조건 및 공모 완료는 시장 조건에 따라 달라질 수 있습니다.
예비 투자설명서 보충자료 및 동행 투자설명서는 SEC에 제출되어, 공모 조건에 대한 자세한 정보를 제공할 것입니다.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI), une entreprise de biotechnologie en phase clinique spécialisée dans les immunothérapies ciblées, a annoncé des projets pour une offre publique d'actions ordinaires et d'options de souscription pré-financées. L'offre sera réalisée par Ladenburg Thalmann & Co. Inc. en tant qu'agent de placement exclusif.
La société a l'intention d'utiliser les revenus pour le fonds de roulement et les fins générales de l'entreprise. Les titres seront offerts par le biais d'une déclaration d'enregistrement sur étagère au moyen du formulaire S-3, déclarée effective par la SEC le 10 octobre 2024. La taille finale, les conditions et l'achèvement de l'offre dépendent des conditions du marché.
Un supplément de prospectus préliminaire et le prospectus d'accompagnement seront déposés auprès de la SEC, fournissant des informations détaillées sur les conditions de l'offre.
Calidi Biotherapeutics (NYSE AMERICAN: CLDI), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf gezielte Immuntherapien spezialisiert hat, hat Pläne für eine öffentliche Angebots von Stammaktien und vorfinanzierten Warrants angekündigt. Das Angebot wird über Ladenburg Thalmann & Co. Inc. als exklusiven Platzierungsagenten durchgeführt.
Das Unternehmen beabsichtigt, die Einnahmen für Betriebskapital und allgemeine Unternehmenszwecke zu verwenden. Die Wertpapiere werden durch eine Shelf-Registrierungsanmeldung auf dem Formular S-3 angeboten, die von der SEC am 10. Oktober 2024 für wirksam erklärt wurde. Die endgültige Größe, die Bedingungen und der Abschluss des Angebots unterliegen den Marktentwicklungen.
Ein vorläufiges Prospektzusatzdokument und das begleitende Prospekt werden bei der SEC eingereicht und bieten detaillierte Informationen über die Angebotsbedingungen.
- Company has an active shelf registration statement allowing for quick capital raising
- Secured Ladenburg Thalmann as placement agent for the offering
- Potential dilution for existing shareholders
- Uncertain offering terms and timing indicate market dependency
- No specific allocation plan for the proceeds beyond general working capital
Insights
This public offering announcement from Calidi Biotherapeutics signals a critical capital-raising initiative that will likely result in significant dilution for existing shareholders. With a relatively small market cap of
The shelf registration (S-3) filed in October 2024 provides flexibility in timing and structure, including the use of pre-funded warrants which can be attractive to certain institutional investors due to beneficial ownership limitations. The lack of specific pricing and size details in the announcement typically indicates the final terms will be determined based on market conditions and investor interest, but biotechnology companies often face pricing at a discount to current market value to ensure successful placement.
The stated use of proceeds for "working capital and general corporate purposes" is notably broad and generic, which could raise concerns about the immediate capital needs and burn rate. For a clinical-stage biotech company, this likely translates to funding ongoing clinical trials and operational expenses.
The timing and structure of this offering reflect the challenging capital markets environment for clinical-stage biotechnology companies. Without specifying a particular clinical program or development milestone as the use of proceeds, this suggests Calidi may be raising funds to extend their operational runway rather than accelerate specific programs. For clinical-stage companies, maintaining sufficient capital reserves is important for negotiating positions with potential partners and advancing clinical trials.
The inclusion of pre-funded warrants in the offering structure is a sophisticated approach that can help attract institutional investors who face ownership limitations while providing immediate capital access to the company. However, this complexity in the offering structure could indicate challenges in attracting straight equity investors at current market prices.
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) in an public offering. All of the shares of common stock (and/or Pre-funded Warrants) are to be sold by the Company.
Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent for the offering.
The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Calidi intends to use the net proceeds from the offering for working capital and for general corporate purposes.
The securities described are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-282456), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on October 10, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the Company and such offering.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described therein, nor shall there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About Calidi Biotherapeutics
Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
Forward-Looking Statements
This press release may contain forward-looking statements for purposes of the “safe harbor” provisions under the United States Private Securities Litigation Reform Act of 1995. Terms such as “anticipates,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predicts,” “project,” “should,” “towards,” “would” as well as similar terms, are forward-looking in nature, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements concerning upcoming key milestones (including the reporting of interim clinical results and the dosing of patients), planned clinical trials, and statements relating to the safety and efficacy of Calidi’s therapeutic candidates in development. Any forward-looking statements contained in this discussion are based on Calidi’s current expectations and beliefs concerning future developments and their potential effects and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that Calidi is not able to raise sufficient capital to support its current and anticipated clinical trials, the risk that early results of clinical trials do not necessarily predict final results and that one or more of the clinical outcomes may materially change following more comprehensive review of the data, and as more patient data becomes available, the risk that Calidi may not receive FDA approval for some or all of its therapeutic candidates. Other risks and uncertainties are set forth in the section entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s Registration Statements filed with the SEC on (i) Form S-4 filed on August 2, 2023 and the corresponding prospectus filed on August 4, 2023, and (ii) on Form S-1 filed on April 15, 2024, and the Company’s periodic reports filed with the SEC on (i) Form 10-K filed on March 15, 2024, (ii) Form 10-Q filed on May 14, 2024, (iii) Form 10-Q filed on August 13, 2024, and (iv) Form 10-Q filed on November 12, 2024. These reports may be amended or supplemented by other reports we file with the SEC from time to time.
For Investors:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
CLDI@redchip.com
FAQ
What is the purpose of Calidi Biotherapeutics' (CLDI) January 2024 public offering?
Who is the placement agent for CLDI's 2024 public offering?
What securities are being offered in CLDI's public offering?
When was CLDI's Form S-3 shelf registration statement declared effective?
How will CLDI use the proceeds from the public offering?
